Kalvista Pharmaceuticals Inc (KALV NASDAQ) stock market data APIs
$16.4886
0.05(0.3%)
as of December 5, 2025
Try our APIs with
free plan!
Kalvista Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Prev. Close
16.4886
Open
16.5386
High
16.7155
Low
15.8858
52 wk Range
7.3-17.28
Market Cap
830 M
Shares Outstanding
50 546 K
Revenue
1 426 K
EPS
-0.92
Beta
-0.138
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kalvista Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kalvista Pharmaceuticals Inc data using free add-ons & libraries
Get Kalvista Pharmaceuticals Inc Fundamental Data
Kalvista Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 1 426 K
- EBITDA: -201 820 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-11
- EPS/Forecast: -0.96
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kalvista Pharmaceuticals Inc News
New
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
Shares of Pharvaris PHVS rose nearly 22% on Wednesday after the company announced positive results from the phase III RAPIDe-3 study evaluating its lead pipeline drug deucrictibant in the hereditary a...
SA Quant ranks Goldman's small-cap stocks with largest short interest
[Multi screen fintech investing gold and silver trading on digital screen corporating with AI artificial intelligence financial business data on commodity investment] primeimages Goldman Sachs analys...
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects
Kalvista Pharmaceuticals Inc. (NASDAQ:KALV) is one of the best breakout stocks to invest in. On November 11, analysts at Citizens lowered their price target of the stock to $28 from $29 while reiterat...
Here are the major earnings before the open Tuesday
Major earnings expected before the bell on Tuesday include: * Nebius Group N.V. (NBIS [https://seekingalpha.com/symbol/NBIS]) * Sea Limited (SE [https://seekingalpha.com/symbol/SE]) * Workhorse...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
